Oncoral Pharma ApS gets an Innobooster grant

September 21, 2016

The Danish Innovation Fund has granted Oncoral Pharma ApS 497.310 DKK as an Innobooster grant to support an open label phase I study to show that their proprietary oral irinotecan tablet product can be taken together with oral capecitabine tablet as a new, safe and effective tablet based treatment to be taken at home.